David Jung

David Jung is a seasoned chemist with extensive experience in medicinal chemistry and drug development. Currently serving as a chemist at SpringWorks Therapeutics since December 2023, David has previously held key roles, including group leader at Agile Sciences and research chemist at RTI International. David's career includes significant contributions at GlaxoSmithKline as a synthetic chemist, focusing on novel templates and lead optimization, as well as advanced research at Memorial Sloan-Kettering Cancer Center, where David worked on the total synthesis of Taxol. David earned a Ph.D. in synthetic organic chemistry from the University of North Carolina at Chapel Hill between 1987 and 1992.